EFFICACY, SAFETY, AND COST-EFFECTIVENESS OF TELMISARTAN AND CILNIDIPINE IN HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE IN A TERTIARY CARE TEACHING HOSPITAL: A PROSPECTIVE COMPARATIVE STUDY

ALTHAB BEGUM MOHAMED; SATYAJIT MOHAPATRA; JERIN JAMES; JANANI L

doi:10.22159/ajpcr.2025v18i11.55273

Authors

ALTHAB BEGUM MOHAMED Department of Pharmacology, Vinayaka Mission’s Medical College and Hospital, Vinayaka Mission’s Research Foundation (DU), Karaikal, Puducherry, India. https://orcid.org/0000-0001-6726-3719
SATYAJIT MOHAPATRA Department of Pharmacology, All India Institute of Medical Sciences, Guwahati, Assam, India. https://orcid.org/0000-0002-7950-1005
JERIN JAMES Department of Pharmacology, SRM Medical College Hospital and Research Centre, Kanchipuram, Tamil Nadu, India. https://orcid.org/0000-0002-5534-9299
JANANI L Department of Community Medicine, Dhanalakshmi Srinivasan Institute of Medical Sciences and Hospital, Perambalur, Tamil Nadu, India. https://orcid.org/0009-0000-6576-8000

DOI:

https://doi.org/10.22159/ajpcr.2025v18i11.55273

Keywords:

Hypertension, Telmisartan, Cilnidipine

Abstract

Objectives: The objective of the study is to evaluate and compare telmisartan with cilnidipine’s cost-efficiency, safety, and effectiveness in hypertensive patients with coronary artery disease (CAD).

Methods: From January 2017 to June 2018, a non-randomized, open-labeled, comparative study was carried out in the SRM Medical College Hospital’s Department of Cardiology. A total of 126 individuals with electrocardiogram-confirmed CAD and hypertension were divided into two groups, each consisting of 63 participants: Telmisartan (40 mg) and cilnidipine (10 mg). Blood pressure, renal function, electrolytes, adverse effects, and costs were measured at baseline, 12 weeks, and 24 weeks.

Results: At both 12 and 24 weeks, telmisartan reduced systolic blood pressure more than the other medication (mean difference at 24 weeks: 5.6 mmHg; p<0.000). Both drugs showed comparable diastolic blood pressure reductions. Although cilnidipine caused a significant drop in serum creatinine (p=0.001), renal parameters stayed constant. Telmisartan was better tolerated than cilnidipine, which had more side effects. The cost-effectiveness of cilnidipine was significantly higher (mean cost difference: Indian rupee 96.8; p<0.000).

Conclusion: Both drugs are effective antihypertensives for people with CAD. While cilnidipine is more affordable, telmisartan provides better blood pressure control and renal safety with acceptable tolerability.

Downloads

Download data is not yet available.

References

1. Rao CR, Kamath VG, Shetty A, Kamath A. High blood pressure prevalence and significant correlates: A quantitative analysis from coastal Karnataka, India. ISRN Prev Med. 2013;2013(1):574973. doi: 10.5402/2013/574973, PMID 24967139

2. Sutters M. Systemic hypertension. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current Medical Diagnosis and TREATMENT 2013. 52nd ed. New York: McGraw-Hill Medical; 2013. p. 1-11.

3. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49(1):12-26. doi: 10.1053/j.ajkd.2006.10.014, PMID 17185142

4. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res. 2009;32(1):3-107. PMID 19300436

5. Khatib OM, El Guindy MS. Clinical guidelines for the management of hypertension. Emro Tech Publ S EMRO. 2005;29:48-78.

6. Bell K, Twiggs J, Olin BR. Hypertension: The silent killer: Updated JNC-8 guideline recommendations. Ala Pharm Assoc. 2015 Jun;334:4222.

7. Sawant R, Suryawanshi S, Jadhav M, Barkate H, Bhushan S, Rane T. A prospective, randomized open-label study for assessment of antihypertensive effect of telmisartan versus cilnidipine using ambulatory blood pressure monitoring (START ABPM study). Cardiol Res. 2023 May 26;14(3):211-20. doi: 10.14740/cr1476, PMID 37304922

8. The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial. Lancet. 2008;372(9644):1174-83. doi: 10.1016/S0140-6736(08)61242-8

9. Shah S, Noor L, Shah SH, Shahsawar, Din SU, Awan ZA, et al. Myocardial infarction in young versus older adults: Clinical characteristics and angiographic features. J Ayub Med Coll Abbottabad. 2010;22(2):187-90.

10. Canto JG, Rogers WG, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, et al. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA. 2012 Feb 22;307(8):813-22.

11. Stevens J, Cai J, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338(1):1-7. doi: 10.1056/nejm199801013380101, PMID 9414324

12. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit. 1998;3(5):295-302. PMID 10212369

13. Gosse P, Neutel J, Schumacher H, Lacourciere Y, Williams B. Reduction of early morning blood pressure surge with telmisartan compared with ramipril in mild-to-moderate hypertensive patients. J Hypertens. 2007;12(3):S375-6.

14. Makawana Y, Panchal PJ. Evaluation of efficacy and safety of cilnidipine and losartan in hypertensive patients with type 2 diabetes mellitus. Int J Med Public Health. 2016;6(1):40-4. doi: 10.4103/2230- 8598.179761

15. Manthri S, Veena D, Ambari RB, Puchchakayala. A prospective interventional study on clinical effects of cilnidipine in hypertensive patients. Int J PharmTech Res. 2015;8(10):70-6.

16. Kaur B, Jyoti N, Kaur G, Arora L. Comparative efficacy and safety of cilnidipine and telmisartan in hypertension: An 8 week, prospective study. Int J Pharm Clin Res. 2024;16(11):115-9.

17. Patel JM, Dhingani AP, Garala KC, Raval MK, Sheth NR. Development and validation of bioanalytical HPLC method for estimation of telmisartan in rat plasma: Application to pharmacokinetic studies. Dhaka Univ J Pharm Sci. 2013;11(2):121-7. doi: 10.3329/dujps. v11i2.14562

18. Bhimani B, Mehta KG, Shah V. Solubility and dissolution rate enhancement of telmisartan via solid dispersion and pelletization. Int J Appl Pharm. 2020;12(1):85-91.

19. Binquan C, Dongyue L, Shangzhong W, Yinggui F. Cilnidipine for treatment of essential hypertension accompanied with type II diabetes mellitus incorporated with kidney dysfunction. China Med. 2010:5(6):1673.

20. Sumbria M, Negi PC, Sahai AK, Kaundal PK. To Compare the effect of telmisartan with metoprolol on arterial stiffness in hypertension: Prospective randomized parallel group trial. Indian Heart J. 2014;66(4):415-21. doi: 10.1016/j.ihj.2014.05.020, PMID 25173199

21. Adake P, Somashekar HS, Mohammed Rafeeq PK, Umar D, Basheer B, Baroudi K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res. 2015;6(2):81-5. doi: 10.4103/2231-4040.154543, PMID 25878978

22. Dalvi K. Advisor M. Practice of Indian physicians towards use of calcium channel blockers in the management of hypertension: A paper based questionnaire survey. Indian Med Gaz. 2015;16(4):34-9.

23. Park C, Wang G, Durthaler JM, Fang J. Cost-effectiveness analyses of antihypertensive medicines: A systematic review. Am J Prev Med. 2017 Dec 1;53(6S2):S131-42. doi: 10.1016/j.amepre.2017.06.020, PMID 29153114

24. Khan MY, Pandit S, Abdulkutty J, Navasundi G, Hazra PK, Phadke U, et al. Effectiveness of telmisartan on blood pressure control in hypertensive patients in India: A real-world retrospective study from electronic medical records. Cardiol Ther. 2021 Jun;10(1):255-69. doi: 10.1007/s40119-021-00217-7, PMID 33830460

25. Yum Y, Kim JH, Joo HJ, Kim YH, Kim EJ. Three-year cardiovascular outcomes of telmisartan in patients with hypertension: An electronic health record-based cohort study. Am J Hypertens. 2024 May 15;37(6):429-37. doi: 10.1093/ajh/hpae012, PMID 38285627